Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accounts Payables (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Accounts Payables for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 23.2% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 23.2% year-over-year, with the annual reading at $653000.0 for FY2025, 57.79% down from the prior year.
  • Accounts Payables hit $1.3 million in Q4 2025 for Vistagen Therapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.0 million in Q3 2022 to a low of $1800.0 in Q4 2021.
  • Historically, Accounts Payables has averaged $1.5 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest YoY gain for Accounts Payables was 88722.22% in 2022; the steepest drop was 99.35% in 2022.
  • Year by year, Accounts Payables stood at $1800.0 in 2021, then soared by 88722.22% to $1.6 million in 2022, then increased by 8.64% to $1.7 million in 2023, then plummeted by 40.18% to $1.0 million in 2024, then rose by 23.2% to $1.3 million in 2025.
  • Business Quant data shows Accounts Payables for VTGN at $1.3 million in Q4 2025, $1.8 million in Q3 2025, and $486000.0 in Q2 2025.